Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 22, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists. (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news
' Possibility of Cure' for Some Patients With CLL'Possibility of Cure' for Some Patients With CLL
Ibrutinib is rapidly changing the treatment landscape in chronic lymphocytic leukemia (CLL), and experts are now talking about the possibility of a cure for some patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Measurable Residual Disease Negativity at a High in Leukemia Trial
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - August 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Drug Duo May Be a Weapon Against a Common Leukemia
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival. (Source: WebMD Health)
Source: WebMD Health - August 1, 2019 Category: Consumer Health News Source Type: news
Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
THURSDAY, Aug. 1, 2019 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib-rituximab is more efficacious than chemoimmunotherapy, according to a study published in the Aug. 1 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2019 Category: Pharmaceuticals Source Type: news
Chronic Leukemia | Medscape Chronic Leukemia | Medscape
Chronic leukemias -- chronic myeloid leukemia and chronic lymphocytic leukemia -- occur mostly in adults and are extremely rare in children and young persons. Chronic lymphocytic leukemia has the highest familial incidence of the leukemias. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
TUESDAY, June 4, 2019 -- Venetoclax-obinutuzumab is associated with longer progression-free survival than chlorambucil-obinutuzumab among patients with untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2019 Category: Pharmaceuticals Source Type: news
IMBRUVICA ® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2019 Category: Pharmaceuticals Source Type: news
Ibrutinib, Venetoclax Active in High - Risk, Seniors With CLL
Findings seen in phase 2 study of combo regimen for first - line treatment of chronic lymphocytic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL
THURSDAY, May 30, 2019 -- For high-risk and older patients with previously untreated chronic lymphocytic leukemia (CLL), the combination of ibrutinib and venetoclax is an active regimen, according to a study published in the May 30 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2019 Category: Pharmaceuticals Source Type: news
Ibrutinib and Venetoclax Combo'Impressive' in Front-Line CLL Ibrutinib and Venetoclax Combo'Impressive' in Front-Line CLL
The combination of ibrutinib and venetoclax has shown ' impressive results ' in the front-line treatment of chronic lymphocytic leukemia (CLL), and may not need to be continued indefinitely.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
